What is PRIME?

PRIME is a European consortium of research institutes, medical centres, companies, and societal stakeholders that is funded through an EU Horizon 2020 grant. From 2020 – 2024, PRIME will aim to unravel the insulin-dependent mechanisms that underly both somatic conditions (i.e. type 2 diabetes, obesity, metabolic syndrome) and brain disorders (i.e. Alzheimer’s disease, obsessive-compulsive disorder, autism spectrum disorders). Until now, very little attention has been paid to the role of insulin signaling in brain disorders, and the overlap (or ‘multimorbidity’) with somatic conditions.

Therefore, through PRIME, we aim to develop tools for improved diagnosis, clinical care and prevention of insulin-related lifespan multimorbidity.

Learn More

News & Events

11 December 2023

8ᵗʰ PRIME Steering Committee meeting

On Monday, 11ᵗʰ December 2023, the 8ᵗʰ PRIME Steering Committee meeting took place. Heading towards the final year of the PRIME project, we had great discussions about our project’s findings on insulin and brain disorders, as well as about our next steps for both research and dissemination.

More News

Social media

more social media